Crescent Biopharma (CBIO) Stock Price, News & Analysis

Company Overview

Crescent Biopharma is a clinical-stage biopharmaceutical company dedicated to developing innovative immunomodulatory therapies for oncology and supportive care. The company’s core mission is to improve patient outcomes by harnessing the body’s immune system to combat cancer and mitigate treatment-related side effects. Crescent Biopharma operates as a fully integrated research and development organization, overseeing discovery, preclinical studies, and clinical trials to advance its proprietary pipeline of small molecules and biologics.

The company’s lead product candidate, plinabulin, is a selective immunomodulator designed to prevent chemotherapy-induced neutropenia and enhance anti-tumor activity in combination with immune checkpoint inhibitors. Plinabulin has demonstrated promising results in Phase 2 clinical trials, showing reductions in neutropenic events and favorable safety profiles. Beyond plinabulin, Crescent Biopharma is advancing additional early-stage assets targeting tumor microenvironment modulation, including novel compounds aimed at stimulating dendritic cell activation and reversing immune suppression within solid tumors.

With a global development footprint, Crescent Biopharma collaborates with leading academic institutions and contract research organizations across North America, Europe, and Asia. These partnerships support multi-regional clinical trials and facilitate regulatory interactions with agencies such as the U.S. Food and Drug Administration and the European Medicines Agency. The company also engages in strategic alliances to leverage external expertise in formulation, biomarker development, and combination therapy design, thereby accelerating its pathway to market.

Founded in 2020 and headquartered in Cambridge, Massachusetts, Crescent Biopharma is led by a management team with deep experience in oncology drug development, regulatory affairs, and commercial strategy. Since its 2022 listing on the NASDAQ Global Market under the ticker CBIO, the company has built a robust operational infrastructure encompassing clinical operations, manufacturing partnerships, and corporate governance—all aimed at delivering transformative therapies to patients worldwide.

Key Stats

• Today's Range: $12.71 to $13.82
• 50-Day Range: N/A
• 52-Week Range: $11.06 to $63.00
• Volume: 342,755 shs
• Average Volume: 75,383 shs
• Market Capitalization: $253.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Strong Buy

Crescent Biopharma Stock Analysis - MarketRank™

Crescent Biopharma scored higher than 65% of companies evaluated by MarketBeat, and ranked 364th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.8 / 5
• Analyst Rating: Strong Buy

Consensus Rating

Crescent Biopharma has received a consensus rating of Strong Buy. The company's average rating score is 3.67, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Crescent Biopharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Crescent Biopharma are expected to grow in the coming year, from ($0.16) to ($0.03) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Crescent Biopharma is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Crescent Biopharma is -0.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Crescent Biopharma has a P/B Ratio of 1.57. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: N/A
• Short Interest Level: N/A

Short Interest

There is no current short interest data available for CBIO.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Crescent Biopharma does not currently pay a dividend.

Dividend Growth

Crescent Biopharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.7 / 5
• Environmental Score: -0.84

Short Interest

There is no current short interest data available for CBIO.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.64

News Sentiment

Crescent Biopharma has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Crescent Biopharma this week, compared to 0 articles on an average week.

Search Interest

4 people have searched for CBIO on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Crescent Biopharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.00% of the stock of Crescent Biopharma is held by insiders.

Percentage Held by Institutions

75.19% of the stock of Crescent Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CBIO Stock Analysis - Frequently Asked Questions

How have CBIO shares performed this year?

Crescent Biopharma's stock was trading at $15.7950 at the beginning of the year. Since then, CBIO shares have decreased by 17.9% and is now trading at $12.96.

How were Crescent Biopharma's earnings last quarter?

Crescent Biopharma, Inc. (NASDAQ:CBIO) announced its quarterly earnings data on Thursday, August, 17th. The biopharmaceutical company reported ($7.00) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($7.00).

When did Crescent Biopharma's stock split?

Crescent Biopharma shares reverse split before market open on Monday, June 16th 2025.The 1-100 reverse split was announced on Thursday, June 12th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 13th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split.

How do I buy shares of Crescent Biopharma?

Shares of CBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Crescent Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Crescent Biopharma investors own include Baozun (BZUN), Inovio Pharmaceuticals (INO), Alibaba Group (BABA), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX), Advanced Micro Devices (AMD) and VBI Vaccines (VBIV).

Company Calendar

• Last Earnings: 8/17/2023
• Today: 7/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:CBIO
• Previous Symbol: NASDAQ:CBIO
• CIK: 1253689
• Web: www.crescentbiopharma.com
• Phone: 617-465-0586
• Fax: 336-480-2107
• Employees: 50
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Crescent Biopharma: $25.00
• High Price Target: $28.00
• Low Price Target: $22.00
• Potential Upside/Downside: +92.9%
• Consensus Rating: Strong Buy
• Rating Score (0-4): 3.67
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): ($46.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.88 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -293.92%
• Return on Assets: -206.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.29
• Quick Ratio: 2.29

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.24 per share
• Price / Book: 1.57

Miscellaneous

• Outstanding Shares: 19,550,000
• Free Float: 18,768,000
• Market Cap: $253.37 million
• Optionable: No Data
• Beta: 1.52